Publication

Stakeholder opinions on value in healthcare

Terkola, R., Antonanzas, F. & Postma, M., Mar-2019, In : European Journal of Hospital Pharmacy: Science and Practice. 26, 2, p. 79-84 6 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • Stakeholder opinions on value in healthcare

    Final publisher's version, 298 KB, PDF document

    Request copy

DOI

Objectives To determine how the value of new medicines is defined from the perspective of different stakeholders in nine European countries.

Methods We carried out an explorative survey by conducting in-depth qualitative interviews with a range of experts with health technology assessment, clinical provision, health economics, payer, academic and industry experience. Experts were asked to distribute 100 points over a predefined list of attributes related to value. In total, 30 interviews were conducted with seven academics, five clinicians, nine economists, five payers and four providers. Each of these categories was represented in responses from France, Germany, the Netherlands and the UK.

Results Comments on the interview guide were all positive. There was substantial variation in definitions of value provided by respondents. Most respondents indicated that delivering benefits to the patient is a prerequisite for a healthcare product to be of value, but only half included costs or resource use in their definition. Quantitative responses showed that effectiveness and efficacy were considered the most important attributes of value, followed by safety and side effects. Lower scores were given to other attributes, such as dignity and individualism, and invasiveness of the treatment. Resources and costs associated with complications and readmissions were considered important by academics and economists, but not clinicians.

Conclusions The interview findings indicate that the value of a drug is subjective in being perceived differently by different stakeholders, and for different treatment types. Future research will require evaluation of the views of a larger number of stakeholders in more and different countries to confirm these findings.

Original languageEnglish
Pages (from-to)79-84
Number of pages6
JournalEuropean Journal of Hospital Pharmacy: Science and Practice
Volume26
Issue number2
Publication statusPublished - Mar-2019

    Keywords

  • ECONOMIC-EVALUATION, TECHNOLOGIES, LIFE

View graph of relations

ID: 92448555